Hikal Ltd Reports Q2 & H1 FY26 Earnings: Revenue at Rs 319 Crore, EBITDA at Rs 8 Crore, and PAT at Rs (35) Crore
Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter and half year ended 30th September 2025. The company reported consolidated revenue of Rs 380.45 crore in Q2 and Rs 699 crore in H1 FY26. EBITDA stood at Rs 25 crore for Q2 and Rs 32 crore for H1 FY26. However, PAT was reported at Rs (23) crore for Q2 and Rs 18 crore for H1 FY26. The pharmaceutical business revenue stood at Rs 190 crore with an EBIT margin of -9.2%. The crop protection business reported revenue of Rs 129 crore with an EBIT margin of -7.4%. Despite challenges, the company expects a strong recovery in Q3 and Q4, supported by improved demand visibility, higher capacity utilization, and the commercialization of new products.
Key Highlights
- Consolidated revenue for Q2 stood at Rs 319 crore with EBITDA at Rs 8 crore.
- Pharmaceutical business revenue stood at Rs 190 crore with an EBIT margin of -9.2%.
- Crop protection business reported revenue of Rs 129 crore with an EBIT margin of -7.4%.
- Hikal expects a strong recovery in Q3 and Q4, supported by improved demand visibility, higher capacity utilization, and the commercialization of new products.
- Hikal has launched a robust remediation program and engaged two globally recognized remediation partners to address US FDA audit observations.